Latest Articles about BIOS

BIOS Misses Earnings Mark But Rev Tops - Analyst Blog

Zacks Equity Research — Thu, 09 May 2013 18:20:01 Z

In the first quarter of 2013, BioScrip Inc. ( BIOS ) posted adjusted earnings per share (EPS) of a penny, better than the year-ago adjusted loss of 2 cents. Nonetheless, the result

Sluggish Segments Sour CVS Earnings Beat - Analyst Blog

Zacks Equity Research — Wed, 01 May 2013 18:51:10 Z

CVS Caremark ( CVS ) reported first-quarter 2013 earnings per share (EPS) of 77 cents, up 29.9% year over year. However, excluding one-time expenses, the adjusted EPS rose 28.1% to 83

Pre-Market Most Active for Apr 19, 2013 : DELL, GE, VOD, QQQ, TOT, MSFT, BAC, VRTX, SAP, NOK, BIOS, DEO

NASDAQ.com News — Fri, 19 Apr 2013 16:39:55 Z

The NASDAQ 100 Pre-Market Indicator is up 16.35 to 2,758.3. The total Pre-Market volume is currently 12,552,022 shares traded. The following are the most active stocks for the pre-market

BioScrip Raised to Outperform - Analyst Blog

Zacks Equity Research — Thu, 11 Apr 2013 01:07:25 Z

On Apr 9, we upgraded our long-term recommendation on BioScrip ( BIOS ) to Outperform from Neutral. The upgradation is based on the avid outlook for 2013, strong potential of its operating

Zacks Rank #1 Addition for Thursday - Tale of the Tape

Zacks Equity Research — Thu, 14 Mar 2013 17:14:31 Z

Here are 5 stocks added to the Zacks Rank #1 ("strong buy") List today: Assured Guaranty Ltd. ( AGO ) BioScrip Inc. ( BIOS ) Churchill Downs, Inc. ( CHDN ) Imation

Mid-Day Market Update: Cabela's Gains On Upbeat Outlook, U.S. Silica Tumbles

Jake L'Ecuyer — Tue, 12 Mar 2013 20:53:45 Z

Midway through trading Tuesday, the Dow traded down 0.03 percent to 14,442.75 while the NASDAQ fell 0.54 percent to 3,235.27. The S&P also fell, dropping 0.29 percent to 1,551.66.

BioScrip Beats; Avid FY13 Outlook - Analyst Blog

Mark Vickery — Tue, 12 Mar 2013 17:30:30 Z

In the fourth quarter of 2012, BioScrip Inc . ( BIOS ) reported net loss from continuing operations of $1.4 million or 3 cents per share, vis-à-vis a net income of $2.6 million or 5

BioScrip Reaffirmed at Neutral - Analyst Blog

Zacks Equity Research — Thu, 21 Feb 2013 00:50:01 Z

We maintain our long-term Neutral recommendation on BioScrip Inc. (BIOS). Although the company has several positive catalysts to drive growth over the long haul, looming concerns keep us on the

Still Neutral on Walgreens - Analyst Blog

Zacks Equity Research — Tue, 22 Jan 2013 00:50:01 Z

We reiterate our Neutral recommendation on Walgreens ( WAG ) following the first quarter fiscal 2013 results. While the company's performance is showing signs of improvement, the current

BioScrip to Buy DaVita Subsidiary - Analyst Blog

Zacks Equity Research — Mon, 17 Dec 2012 20:30:01 Z

Specialty pharmacy services provider, BioScrip Inc. ( BIOS ), recently took a step forward to further strengthen its Infusion Services business by entering into an agreement with DaVita

BioScrip Beats, Margins Down - Analyst Blog

Zacks Equity Research — Mon, 12 Nov 2012 19:30:01 Z

Specialty pharmacy services provider, BioScrip Inc. ( BIOS ) reported a loss of a penny per share from continued operations in the third quarter of fiscal 2012, flat year over year.

Yet Another Buy for Walgreen - Analyst Blog

Zacks Equity Research — Wed, 19 Sep 2012 23:23:01 Z

Despite several recent headwinds, Walgreen ( WAG ) has been successful in maintaining its nonstop shopping spree. Following a gigantic $6.7 billion merger with Alliance Boots, this leading

BioScrip Remains Neutral - Analyst Blog

Zacks Equity Research — Sat, 25 Aug 2012 00:32:18 Z

We are maintaining our Neutral recommendation on BioScrip Inc. ( BIOS ) with a target price of $8.00. BioScrip reported a loss of 7 cents per share from continued operations in the second

BioScrip EPS Misses, Revenue Beats - Analyst Blog

Zacks Equity Research — Fri, 10 Aug 2012 00:15:01 Z

Specialty pharmacy services provider, BioScrip Inc. ( BIOS ) reported a loss of 7 cents per share from continued operations in the second quarter of fiscal 2012, worse than the year-ago

Walgreen Remains Neutral - Analyst Blog

Zacks Equity Research — Sat, 07 Jul 2012 02:47:01 Z

Recently, we have reiterated our Neutral recommendation on Walgreen ( WAG ) with a target price of $31.00. Walgreen reported EPS of 62 cents per share in the third quarter of fiscal 2012,